Interferon-α enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models

Cancer Science

Volumn 99, Issue 12, 2008, Pages 2461-2466

  Kawai, Shigeto ^a   Azuma, Yumiko ^a   Fujii, Etsuko ^b   Furugaki, Kou ^a   Ozaki, Shuji ^d   Matsumoto, Toshio ^d   Kosaka, Masaaki ^e   Yamada Okabe, Hisafumi ^a,c  

^a Chugai Pharmaceutical   (Japan)

^b Chugai Pharmaceutical   (Japan)

^c Research Planning and Coordination Department   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e Tokushima Red Cross Blood Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD ANTIGEN; CD317 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD317; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; MICE, SCID; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57349089289     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00968.x     Document Type: Article

References (19)

1. Ohtomo T, Sugamata Y, Ozaki Y et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 1999; 258: 583-91.
2. Goto T, Kennel SJ, Abe M et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994; 84: 1922-30.
3. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451: 425-30.
4. Ono K, Ohtomo T, Yoshida K et al. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol Immunol 1999; 36: 387-95.
5. Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 1997; 90: 3179-86.
6. Kawai S, Yoshimura Y, Iida S et al. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol Rep 2006; 15: 361-7.
7. Powles R, Yong K, Sirohi B et al. Humanized anti-HM1.24 antibody (AHM): phase I study in patients with relapsed or refractory myeloma. Proceedings of the Japanese Multiple Myeloma Forum; 3 November 2003, Hokkaido, Japan.
8. Amato RJ. Renal cell carcinoma: Review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005; 16: 7-15.
9. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94: 614-19.
10. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
11. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17.600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34.
12. Queirolo P, Acquati M, Kirkwood JM et al. Update: Current management issues in malignant melanoma. Melanoma Res 2005; 15: 319-24.
13. Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin, and interferon-α-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23: 6747-55.
14. Pavlick AC, Adams S, Fink MA, Bailes A. Novel therapeutic agents under investigation for malignant melanoma. Expert Opin Invest Drugs 2003; 12: 1545-58.
15. Ozaki S, Kosaka M, Wakahara Y et al. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 1999; 93: 3922-30.
16. Kawai S, Koishihara Y, Iida S et al. Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: Correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24. Leuk Res 2006; 30: 949-56.
17. Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM. Anti-renal cell carcinoma chimeric antibody G250: Cytokine enhancement of in.vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2002; 51: 171-7.
18. Bleumer I, Knuth A, Oosterwijk E et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004; 90: 985-90.
19. Ge Y, Dombkowski AA, LaFiura KM et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 2006; 107: 1570-82.